Page last updated: 2024-11-07

l-lactic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L-lactic acid is a chiral organic compound with the formula CH3CH(OH)CO2H. It is a white, hygroscopic solid that is soluble in water and ethanol. L-lactic acid is a naturally occurring compound that is found in many foods, such as yogurt, sauerkraut, and pickles. It is also produced by the body during exercise and other metabolic processes. L-lactic acid is used in a variety of applications, including food production, pharmaceuticals, and cosmetics. It is also used in the production of biodegradable plastics. L-lactic acid is an important metabolite in the human body and plays a role in energy production and muscle function. Research on l-lactic acid is ongoing, with particular focus on its potential applications in medicine, such as the treatment of cancer and diabetes. '

(S)-lactic acid : An optically active form of lactic acid having (S)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107689
CHEMBL ID330546
CHEBI ID422
MeSH IDM0585517

Synonyms (114)

Synonym
CHEMBL330546
gtpl2932
lactic acid, l-
l-(+)-alpha-hydroxypropionic acid
l-milchsaeure
(s)-2-hydroxypropionic acid
(s)-2-hydroxypropanoic acid
(+)-lactic acid
(s)-(+)-lactic acid
l-(+)-lactic acid
CHEBI:422 ,
brn 1720251
fleischmilchsaeure
(s)-milchsaeure
paralactic acid
paramilchsaeure
(s)-2-hydroxypropionsaeure
einecs 201-196-2
propanoic acid, 2-hydroxy-, (2s)-
sarcolactic acid
tisulac
purac
ph 90
acidum sarcolacticum
propanoic acid, 2-hydroxy-, (s)-
NCHEMBIO867-COMP9
l-(+)-lactic acid, 80%
2OP ,
(2s)-2-hydroxypropanoic acid
C00186
79-33-4
l-lactic acid
(s)-lactic acid
l-(+)-lactic acid, >=98%
l-(+)-lactic acid, bioxtra, >=98% (titration)
l-(+)-lactic acid, analytical standard
l lactic acid
L-0990
L-1000
l-lactic acid, crystalline, 98.0%+
5E39D33D-2F71-4C24-BC7A-5E6F27E4CF83
BMSE000208
l(+)-lactic acid
L0165
l-milchsaure
plla
BMSE000818
BMSE000979
4-03-00-00633 (beilstein handbook reference)
unii-f9s9ffu82n
f9s9ffu82n ,
l(+)-2-hydroxypropionsaeure
ec 201-196-2
sarcolacticum acidum
pleo sanvis
S6250
l-lactic acid [mi]
dextrorotatory lactic acid
sarcolactic acid [who-dd]
(s)-lactic acid [ep monograph]
l-lactic acid [jan]
l- lactic acid (+)
sarcolacticum acidum [hpus]
lactic acid, l- [ii]
(s)(+)-2 hydroxypropionic acid
(s)(+)2 hydroxypropionic acid
l-iactic acid
l-(+) lactic acid
(s)-2-hydroxy-propionic acid
AKOS025146504
1-hydroxyethane 1-carboxylic acid
2-hydroxypropanoic acid, (s)- #
mfcd00064266
DTXSID6034689
l-lactic acid, anhydrous
D71144
l-(+)-lactic acid, vetec(tm) reagent grade, 86%
a-hydroxypropionate
l-(+)-lactic acid solution
alpha-hydroxypropionate
a-hydroxypropanoate
(s)-2-hydroxy-propanoic acid
(s)-2-hydroxypropionate
1-hydroxyethane 1-carboxylate
a-hydroxypropanoic acid
(s)-2-hydroxypropanoate
(s)-2-hydroxy-propanoate
(s)-(+)-2-hydroxypropanoate
l-2-hydroxypropanoate
(alpha)-lactate
1-hydroxyethanecarboxylate
alpha-hydroxypropanoate
(alpha)-lactic acid
(s)-(+)-2-hydroxypropanoic acid
l-2-hydroxypropanoic acid
a-hydroxypropionic acid
HY-Y0479
CS-0015266
FT-0773848
DB14475
Q27080955
EN300-91905
l-lactic acid, 90%
l-lacticacid
l-(+)-lactic acid 95% liquid
l+lactic acid, free acid (s)-2-hydroxypropionic acid, sarcolactic acid
l-(+)-lactic acid solution, 1m
80% (w/w) lactic acid solution
clo2-c activator
lactic acid, l-(ii)
lactisan winter
pleo sanuvis
l-lactic acid (+)
(s)-lactic acid (ep monograph)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-hydroxypropanoic acidA 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
(2S)-2-hydroxy monocarboxylic acidA 2-hydroxy monocarboxylic acid in which the carbon at position 2 has (S)-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (53)

PathwayProteinsCompounds
Transport of small molecules39295
SLC-mediated transmembrane transport13567
Transport of bile salts and organic acids, metal ions and amine compounds4928
Organic cation/anion/zwitterion transport67
Organic anion transport13
Metabolism14961108
The citric acid (TCA) cycle and respiratory electron transport14756
Pyruvate metabolism and Citric Acid (TCA) cycle4146
Pyruvate metabolism2026
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Hydroxycarboxylic acid-binding receptors31
GPCR downstream signalling17252
G alpha (i) signalling events8741
Pyruvate Metabolism2139
Gluconeogenesis2232
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
Fucose and Rhamnose Degradation1218
L-Lactaldehyde Degradation (Aerobic)27
Methylglyoxal Degradation IV410
Methylglyoxal Degradation I39
Glutaminolysis and Cancer3536
Disease1278231
Disorders of transmembrane transporters10243
SLC transporter disorders4537
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)02
NAD+ + (S)-Lactic acid = NADH + Pyruvic acid ( Pyruvate metabolism )44
Pyruvate metabolism ( Pyruvate metabolism )3027
Aerobic glycolysis020
Metabolic pathways of fibroblasts1718
Metabolic Epileptic Disorders2589
AtMetExpress overview0109
HIF1A and PPARG regulation of glycolysis07
TCA cycle nutrient use and invasiveness of ovarian cancer04
Biochemical pathways: part I0466
NAD+ metabolism014
Amino acid metabolism094
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017
Glucose homeostasis021

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Monocarboxylate transporter 1Rattus norvegicus (Norway rat)Km2.28002.28002.66503.0500AID679949
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1378235Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification.
AID1378236Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification.
AID679949TP_TRANSPORTER: uptake in MCT1-expressing MDA-MB231 cells1999The Journal of pharmacy and pharmacology, Oct, Volume: 51, Issue:10
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID679948TP_TRANSPORTER: uptake in Xenopus laevis oocytes1995Biochemical and biophysical research communications, Dec-05, Volume: 217, Issue:1
cDNA cloning and functional characterization of rat intestinal monocarboxylate transporter.
AID1346417Human HCA1 receptor (Hydroxycarboxylic acid receptors)2009The Journal of biological chemistry, Jan-30, Volume: 284, Issue:5
Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81.
AID1346417Human HCA1 receptor (Hydroxycarboxylic acid receptors)2010Cell metabolism, Apr-07, Volume: 11, Issue:4
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81.
AID1346417Human HCA1 receptor (Hydroxycarboxylic acid receptors)2008Biochemical and biophysical research communications, Dec-19, Volume: 377, Issue:3
Role of GPR81 in lactate-mediated reduction of adipose lipolysis.
AID1346417Human HCA1 receptor (Hydroxycarboxylic acid receptors)2013Journal of biomolecular screening, Jun, Volume: 18, Issue:5
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.68 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index75.56 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (49.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]